ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2152 entries already.
A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO).
Fiasco in Phase III: Roche’s conditionally approved PD-L1 checkpoint inhibitor did not meet the endpoint of overall survival vs chemotherapy in a confirmatory study with pre-treated patients with metastatic urothelial cancer.
Mucosal inflammation specialist Dermtreat ApS (Copenhagen) has secured a Series A financing worth €16.2m (US$17.7m).
GMO world market adoption is further growing. GMO cultivation area in 2016 increased to 185.1 million hectares versus 2015 (179.7m hectares), 3% up globally, and from 116,870 in 2015 to 136,363 hectares, 17% up, in the EU.
With an impressive 11.7% growth in sales compared with 2015, the Swiss biotech sector has grown more strongly in 2016 than the years before. However, after three years of growth, Swiss biotech companies collected almost CHF100m less than in the previous year, according to the most recent Swiss Biotech Report.
The Biotechnology in Germany is a growth engine. According to a new report, all key figures such as employees, turnover and R&D expenditure were at an all-time high in 2016.
The french biotechnology company Vivet Therapeutics has raised €37.5 million in a Series A financing round. Amongst others, Novartis Venture Fund and Roche Venture Fund were involved.
The Boehringer Ingelheim Venture Fund leads a financing consortium that collected €20m for French cancer therapy developer Imcheck. The Marseille-based company also presented its new CEO.
The French biotech said that its lead therapeutic candidate demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients. Following the news, the company’s share price more than doubled.
British respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ through the issuance of 5,768,000 American Depositary Shares (ADS) – each ADS representing eight ordinary shares – at a price of US-$13.50 per ADS.